Adial Pharmaceuticals ADILW 深 滬
已收盤 07-27 16:00:00 美东时间
0.0009
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.0009
- 總市值 1.58万
- 52周最高 0.199
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.0004
- 委 比 0.00%
- 總股本 1750.35万
- 歷史最高 2.45
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.00
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Adial Pharmaceuticals Completes Azora Merger, Shifts Strategic Focus
Adial Pharmaceuticals ( ($ADIL) ) has issued an update. On June 11, 2026, Adial...
06-12 00:57
Adial Pharmaceuticals Acquires Azora Therapeutics In All-Stock Transaction, Enters Concurrent Private Placement To Raise Up To $64M
About the Transactions The acquisition of Azora was structured as an asset acquisition pursuant to which all of Azora's outstanding equity interests were exchanged, based on a fixed exchange ratio, for a combination of 437,474 shares of Adial common stock and approximately 12,930 shares of Adial Ser...
06-11 23:51
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
Adial Pharmaceuticals acquired Azora Therapeutics, gaining its lead asset AT177, an oral, colon-targeted AhR agonist for ulcerative colitis designed to minimize systemic exposure. Concurrently, Adial secured $64 million in private placement financing, with $32 million upfront and potential for an additional $32 million upon Phase 1 initiation. The funds will advance AT177 through key clinical milestones, including IND-enabling studies and Phase 1...
06-11 15:43
Adial Pharmaceuticals Q1 net loss narrows on lower R&D spending
Adial Pharmaceuticals Q1 net loss narrows on lower R&D spending Overview U.S. addiction therapies developer's Q1 net loss narrowed from prior year on lower R&D spending Company highlighted regulatory changes that may speed AD04 approval and reduce development costs Adial set collaboration framework
05-11 20:38
Adial Pharmaceuticals Q1 EPS $(1.48) Beats $(2.73) Estimate
Adial Pharmaceuticals (NASDAQ:ADIL) reported quarterly losses of $(1.48) per share which beat the analyst consensus estimate of $(2.73) by 45.79 percent. This is a 82.59 percent increase over losses of $(8.50) per share
05-09 06:15
EXCLUSIVE: Adial Pharmaceuticals Clears Manufacturing Milestone Ahead Of Pivotal Study For Alcohol Use Disorder Drug
Adial Pharmaceuticals completes AD04 demo batch, validating process transfer and enabling Phase 3 production and FDA IND updates.
04-22 21:21
Adial Pharmaceuticals Implements New Executive Equity Compensation Plan
Adial Pharmaceuticals ( ($ADIL) ) just unveiled an announcement. On April 7, 20...
04-10 05:37
Adial Pharmaceuticals Lead Drug Fits New Policy Mood As Bipartisan Bill Signals Broader Lens On Alcohol Use Disorder
Adial backs H.R. 7091 targeting AUD in veterans, spotlighting harm reduction therapies and expanding research beyond abstinence-based care.
03-24 21:13
Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans
U.S. Congress has introduced H.R. 7091, the Expanding Veterans’ Access to Emerging Treatments Act, to expand research and development of therapies for conditions affecting U.S. veterans, including Alcohol Use Disorder (AUD). The bill aligns with updated federal recovery standards, supporting non-abstinence-based treatments. Adial Pharmaceuticals, Inc. commends this bipartisan legislation, noting its potential to advance therapies like their inves...
03-24 13:07
Adial Pharmaceuticals Q4 EPS $(11.48) Misses $(0.09) Estimate
Adial Pharmaceuticals (NASDAQ:ADIL) reported quarterly losses of $(11.48) per share which missed the analyst consensus estimate of $(0.09) by 12655.56 percent. This is a 206.13 percent decrease over losses of $(3.75) per
03-06 21:07
